1. Home
  2. MSB vs IVVD Comparison

MSB vs IVVD Comparison

Compare MSB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesabi Trust

MSB

Mesabi Trust

HOLD

Current Price

$25.70

Market Cap

334.0M

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.10

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSB
IVVD
Founded
1961
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
334.0M
437.1M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
MSB
IVVD
Price
$25.70
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.75
AVG Volume (30 Days)
57.5K
2.4M
Earning Date
04-24-2026
05-08-2026
Dividend Yield
4.80%
N/A
EPS Growth
391.29
79.02
EPS
0.85
N/A
Revenue
$98,595,651.00
$53,426,000.00
Revenue This Year
N/A
$61.57
Revenue Next Year
N/A
$41.42
P/E Ratio
$30.10
N/A
Revenue Growth
331.26
110.47
52 Week Low
$22.55
$0.49
52 Week High
$42.38
$3.07

Technical Indicators

Market Signals
Indicator
MSB
IVVD
Relative Strength Index (RSI) 32.99 34.88
Support Level $25.24 $0.49
Resistance Level $32.73 $1.14
Average True Range (ATR) 1.72 0.11
MACD -0.22 -0.03
Stochastic Oscillator 20.60 13.51

Price Performance

Historical Comparison
MSB
IVVD

About MSB Mesabi Trust

Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the northeastern end of the Mesabi Iron Range.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: